[A19-76] Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Commission awarded on 30.08.2019 by the Federal Joint Committee (G-BA).
Adults treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to major bleeding
No comparison with appropriate comparator therapy possible; therefore added benefit currently not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-02||Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76||Commission completed|
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.